Epicrispr Biotechnologies
South San Francisco
About Epicrispr Biotechnologies
The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent, which means that a single GEMS design can address the majority or all genetic subtypes of a disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $123.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2025)
- Website: epic-bio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/epicrispr-biotechnologies-2441 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.